| scholarly article | Q13442814 |
| P2093 | author name string | Dhrubajyoti Bandyopadhyay | |
| Raktim Kumar Ghosh | |||
| Ashish Aneja | |||
| Gopal Chandra Ghosh | |||
| Krishnarpan Chatterjee | |||
| P2860 | cites work | Regulation of intracellular Na(+) in health and disease: pathophysiological mechanisms and implications for treatment | Q26863221 |
| Pharmacology at work for cardio-oncology: ranolazine to treat early cardiotoxicity induced by antitumor drugs | Q27006960 | ||
| Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome | Q33872995 | ||
| Inhibition of the late sodium current slows t-tubule disruption during the progression of hypertensive heart disease in the rat. | Q33891370 | ||
| Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure. | Q33916951 | ||
| 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, a | Q34312742 | ||
| Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties | Q34339876 | ||
| Ranolazine: a new approach to treating an old problem | Q34457675 | ||
| Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial | Q34544699 | ||
| Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina | Q34547211 | ||
| Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial | Q34569443 | ||
| Sodium channel slow inactivation as a therapeutic target for myotonia congenita | Q35044306 | ||
| Effect of Ranolazine Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes | Q35769527 | ||
| Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial | Q35810820 | ||
| Ranolazine stabilizes cardiac ryanodine receptors: a novel mechanism for the suppression of early afterdepolarization and torsades de pointes in long QT type 2. | Q35911288 | ||
| Effects of ranolazine on exercise capacity, right ventricular indices, and hemodynamic characteristics in pulmonary arterial hypertension: a pilot study | Q36016535 | ||
| Effect of ranolazine on left ventricular dyssynchrony in patients with coronary artery disease. | Q36354376 | ||
| Clinical pharmacokinetics of ranolazine | Q36460838 | ||
| Ranolazine versus amiodarone for prevention of postoperative atrial fibrillation. | Q36534150 | ||
| Reduced immunoreactivities of B-type natriuretic peptide in pulmonary arterial hypertension rats after ranolazine treatment | Q36760329 | ||
| Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome | Q37038494 | ||
| The Effects of Ranolazine on Paroxysmal Atrial Fibrillation in Patients with Coronary Artery Disease: A Preliminary Observational Study. | Q37115123 | ||
| Late sodium current inhibition as a new cardioprotective approach | Q37156945 | ||
| Pathophysiology of the cardiac late Na current and its potential as a drug target | Q37276416 | ||
| Fibroblast growth factor 23 dysregulates late sodium current and calcium homeostasis with enhanced arrhythmogenesis in pulmonary vein cardiomyocytes | Q37688345 | ||
| Targeting fatty acid and carbohydrate oxidation--a novel therapeutic intervention in the ischemic and failing heart. | Q37831555 | ||
| Ranolazine in the prevention of anthracycline cardiotoxicity. | Q38165595 | ||
| Ranolazine treatment for myocardial infarction? Effects on the development of necrosis, left ventricular function and arrhythmias in experimental models | Q38238926 | ||
| Phase I safety study of ranolazine in pulmonary arterial hypertension | Q38398135 | ||
| Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial | Q38400391 | ||
| The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism | Q38407016 | ||
| Combined actions of ivabradine and ranolazine reduce ventricular rate during atrial fibrillation | Q38547436 | ||
| Ranolazine preserves and improves left ventricular ejection fraction and autonomic measures when added to guideline-driven therapy in chronic heart failure | Q38725641 | ||
| Ranolazine Added to Amiodarone Facilitates Earlier Conversion of Atrial Fibrillation Compared to Amiodarone-Only Therapy. | Q38969897 | ||
| Role of Ranolazine in cardiovascular disease and diabetes: Exploring beyond angina | Q39006483 | ||
| Ranolazine for rhythm control in atrial fibrillation: A systematic review and meta-analysis | Q39006983 | ||
| Ranolazine improves insulin resistance in non-diabetic patients with coronary heart disease. A pilot study. | Q39669941 | ||
| Blockade of Na+ channels in pancreatic α-cells has antidiabetic effects | Q42458638 | ||
| Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy | Q43741617 | ||
| RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study | Q44596273 | ||
| Ranolazine enhances the antiarrhythmic activity of amiodarone by accelerating conversion of new-onset atrial fibrillation after cardiac surgery | Q44627954 | ||
| Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome | Q44805574 | ||
| Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). | Q45038648 | ||
| Atrial-ventricular differences in rabbit cardiac voltage-gated Na+ currents: Basis for atrial-selective block by ranolazine | Q45070399 | ||
| Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (RIVER-PCI) trial | Q45195984 | ||
| Ranolazine for the treatment of heart failure with preserved ejection fraction: background, aims, and design of the RALI-DHF study | Q45413079 | ||
| Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin. | Q45936839 | ||
| Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial | Q46059602 | ||
| Ranolazine increases β-cell survival and improves glucose homeostasis in low-dose streptozotocin-induced diabetes in mice | Q46163409 | ||
| Selective late INa inhibition by GS-458967 exerts parallel suppression of catecholamine-induced hemodynamically significant ventricular tachycardia and T-wave alternans in an intact porcine model | Q46432078 | ||
| Ranolazine improves oxidative stress and mitochondrial function in the atrium of acetylcholine-CaCl2 induced atrial fibrillation rats | Q46544656 | ||
| First direct comparison of the late sodium current blocker ranolazine to established antiarrhythmic agents in an ischemia/reperfusion model | Q48299852 | ||
| The combined effects of ranolazine and dronedarone on human atrial and ventricular electrophysiology | Q48746789 | ||
| Antiarrhythmic Effects of Combining Dofetilide and Ranolazine in a Model of Acutely Induced Atrial Fibrillation in Horses. | Q49183821 | ||
| Cardioprotective Effect of Ranolazine in the Process of Ischemia-reperfusion in Adult Rat Cardiomyocytes | Q50440240 | ||
| Antiarrhythmic effects of ranolazine used both alone for prevention of atrial fibrillation and as an add-on to intravenous amiodarone for its pharmacological cardioversion: a meta-analysis. | Q50652981 | ||
| Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy. | Q50864373 | ||
| Effects of ranolazine in a model of doxorubicin-induced left ventricle diastolic dysfunction. | Q51093490 | ||
| Effect of ranolazine in preventing postoperative atrial fibrillation in patients undergoing coronary revascularization surgery. | Q51540903 | ||
| Comparison of vernakalant and ranolazine in atrial fibrillation. | Q51843072 | ||
| Ranolazine in the treatment of atrial fibrillation: Results of the dose-ranging RAFFAELLO (Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion) study. | Q52870456 | ||
| Long-term administration of ranolazine attenuates diastolic dysfunction and adverse myocardial remodeling in a model of heart failure with preserved ejection fraction. | Q53608890 | ||
| 2013 ESC guidelines on the management of stable coronary artery disease | Q57243329 | ||
| Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease | Q72585308 | ||
| A pilot study of ranolazine in patients with intermittent claudication | Q79429031 | ||
| Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less | Q81097337 | ||
| [Management of refractory symptoms in hypertrophic cardiomyopathy with restrictive pathophysiology: novel perspectives for ranolazine] | Q83864875 | ||
| Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting | Q84501480 | ||
| Ranolazine injection into coronary or femoral arteries exerts marked, transient regional vasodilation without systemic hypotension in an intact porcine model | Q85002021 | ||
| Short-course of ranolazine prevents postoperative atrial fibrillation following coronary artery bypass grafting and valve surgeries | Q86038219 | ||
| Ranolazine enhances the efficacy of amiodarone for conversion of recent-onset atrial fibrillation | Q87183306 | ||
| Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension | Q87623425 | ||
| Open-label trial of ranolazine for the treatment of myotonia congenita | Q88525062 | ||
| P433 | issue | 3 | |
| P921 | main subject | coronary artery disease | Q844935 |
| P304 | page(s) | 88-98 | |
| P577 | publication date | 2018-07-01 | |
| P1433 | published in | Heart Views | Q15816937 |
| P1476 | title | Ranolazine: Multifaceted Role beyond Coronary Artery Disease, a Recent Perspective | |
| P478 | volume | 19 |
Search more.